- Home
- BBWI vs GH Comparison
BBWI vs GH Comparison
Compare BBWI & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBWI
- GH
- Stock Information
- Founded
- BBWI 1963
- GH 2011
- Country
- BBWI United States
- GH United States
- Employees
- BBWI N/A
- GH N/A
- Industry
- BBWI Clothing/Shoe/Accessory Stores
- GH Medical Specialities
- Sector
- BBWI Consumer Discretionary
- GH Health Care
- Exchange
- BBWI Nasdaq
- GH Nasdaq
- Market Cap
- BBWI 5.3B
- GH 4.9B
- IPO Year
- BBWI N/A
- GH 2018
- Fundamental
- Price
- BBWI $24.41
- GH $88.51
- Analyst Decision
- BBWI Buy
- GH Strong Buy
- Analyst Count
- BBWI 17
- GH 22
- Target Price
- BBWI $38.28
- GH $66.27
- AVG Volume (30 Days)
- BBWI 5.7M
- GH 2.1M
- Earning Date
- BBWI 11-24-2025
- GH 10-29-2025
- Dividend Yield
- BBWI 3.07%
- GH N/A
- EPS Growth
- BBWI N/A
- GH N/A
- EPS
- BBWI 3.38
- GH N/A
- Revenue
- BBWI $7,371,000,000.00
- GH $902,569,000.00
- Revenue This Year
- BBWI $4.22
- GH $28.28
- Revenue Next Year
- BBWI $2.93
- GH $23.00
- P/E Ratio
- BBWI $7.36
- GH N/A
- Revenue Growth
- BBWI N/A
- GH 30.38
- 52 Week Low
- BBWI $24.81
- GH $21.28
- 52 Week High
- BBWI $41.87
- GH $73.31
- Technical
- Relative Strength Index (RSI)
- BBWI 37.05
- GH 79.81
- Support Level
- BBWI $26.03
- GH $68.02
- Resistance Level
- BBWI $27.40
- GH $73.31
- Average True Range (ATR)
- BBWI 0.82
- GH 3.29
- MACD
- BBWI -0.06
- GH 1.43
- Stochastic Oscillator
- BBWI 4.17
- GH 87.72
About BBWI Bath & Body Works Inc.
Bath & Body Works is a specialty home fragrance and fragrant body care retailer operating under the Bath & Body Works, C.O. Bigelow, and White Barn brands. The company generates most of its business in North America, with just 5% of sales from international markets in fiscal 2024. For fiscal 2024, 76% of sales stemmed from the brick-and-mortar network (which was composed of more than 1,800 retail stores), similar to 2023 levels, as consumer shopping patterns remained to normal. Future growth is expected from store upgrades, digital and international channels, as well as adjacent category expansions like hair and laundry.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.